Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.

Saved in:
Bibliographic Details
Title: Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.
Authors: Kim DH; Department of Internal Medicine, Seoul National University Hospital, Seoul, the Republic of Korea; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, the Republic of Korea., Kim M; Department of Internal Medicine, Seoul National University Hospital, Seoul, the Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, the Republic of Korea., Youk J; Department of Internal Medicine, Seoul National University Hospital, Seoul, the Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, the Republic of Korea., Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, the Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, the Republic of Korea., Lee GW; Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Institute of Medical Science, Gyeongsang National University College of Medicine, Jinju, the Republic of Korea., Kim SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, the Republic of Korea., Kim YJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, the Republic of Korea., Kim JS; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, the Republic of Korea., Hong SH; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, the Republic of Korea., Ahn MS; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, the Republic of Korea., Shin SH; Department of Internal Medicine, Kosin University Gospel Hospital, Busan, the Republic of Korea., Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, the Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, the Republic of Korea., Kim JH; Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, the Republic of Korea., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, the Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, the Republic of Korea. Electronic address: bhumsuk@snu.ac.kr.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Mar; Vol. 213, pp. 108916. Date of Electronic Publication: 2026 Jan 11.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-8332
DOI:10.1016/j.lungcan.2026.108916